Letrozole versus Anastrozole for Height Augmentation in Short Pubertal Males.
http://press.endocrine.org/doi/abs/10.1210/jc.2014-2432
To investigate short- and long-term hormonal and auxologic differences in short pubertal boys treated with letrozole (L) or anastrozole (A).
Boys with age >10 years, bone age ≤14 years, clinical and hormonal evidence of central puberty, and either height <fifth percentile or predicted adult height (PAH) more than 10 cm below mid-parental height (MPH).
Letrozole (2.5mg) or anastrozole (1mg) was administered orally each day.
Thirty-nine boys have completed one year of treatment. Baseline means were age 14.1 years, PAH 166 cm, and testosterone 198 ng/dl.
At one year, letrozole resulted in higher LH (L 6.1±2.5 vs A 3.2±1.7 IU/L) and testosterone (1038±348 vs 536±216 ng/dl) with lower estradiol (2.8±2.8 vs 5.6±2.9 pg/ml) and IGF-1 (237±51 vs 331±79 ng/ml).
First year growth velocities were identical (7.2 cm/yr), but increase in PAH was greater in the anastrozole group (4.2±3.5 vs 1.4±4.4 cm, p=0.03) after one year.
Letrozole was more potent in hormonal manipulation than anastrozole.
First-year growth velocities were comparable, but improvement in PAH was greater in the anastrozole group.
It remains to be seen if positive PAH trends will translate to increase in final height in either group.
http://press.endocrine.org/doi/abs/10.1210/jc.2014-2432
To investigate short- and long-term hormonal and auxologic differences in short pubertal boys treated with letrozole (L) or anastrozole (A).
Boys with age >10 years, bone age ≤14 years, clinical and hormonal evidence of central puberty, and either height <fifth percentile or predicted adult height (PAH) more than 10 cm below mid-parental height (MPH).
Letrozole (2.5mg) or anastrozole (1mg) was administered orally each day.
Thirty-nine boys have completed one year of treatment. Baseline means were age 14.1 years, PAH 166 cm, and testosterone 198 ng/dl.
At one year, letrozole resulted in higher LH (L 6.1±2.5 vs A 3.2±1.7 IU/L) and testosterone (1038±348 vs 536±216 ng/dl) with lower estradiol (2.8±2.8 vs 5.6±2.9 pg/ml) and IGF-1 (237±51 vs 331±79 ng/ml).
First year growth velocities were identical (7.2 cm/yr), but increase in PAH was greater in the anastrozole group (4.2±3.5 vs 1.4±4.4 cm, p=0.03) after one year.
Letrozole was more potent in hormonal manipulation than anastrozole.
First-year growth velocities were comparable, but improvement in PAH was greater in the anastrozole group.
It remains to be seen if positive PAH trends will translate to increase in final height in either group.
